Johns Hopkins Medicine researchers published clinical validation supporting the first FDA-cleared rapid urine test to aid diagnosis of invasive aspergillosis. The clearance is a practical step toward faster diagnostic workflows for a high-mortality condition where treatment delays can be costly. A rapid urine-based approach can reduce dependence on slower culture-based methods or imaging-heavy pathways, potentially enabling clinicians to refine empiric antifungal decisions earlier in suspected disease—especially for immunocompromised patients where differential diagnosis is time-sensitive. For the diagnostic market, FDA clearance also strengthens the pathway for reimbursement conversations and hospital adoption, often the gating factor for moving from promising biomarkers to consistent clinical utility.